Trophos has positive outlook after funding extension and tax credits
This article was originally published in Scrip
Executive Summary
Trophos, the French pharmaceutical company focused on neurology and cardiology therapies, has extended its partnership with the Association Française contre les Myopathies (AFM) to fund the further clinical development of its lead candidate olesoxime (TRO19622) as a treatment for spinal muscular atrophy (SMA).